Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report released on Monday,Benzinga reports. HC Wainwright currently has a $25.00 price target on the stock. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2028 earnings at $0.43 EPS and FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Price Performance

NASDAQ:MIST opened at $1.99 on Monday. The firm has a market capitalization of $106.12 million, a price-to-earnings ratio of -2.46 and a beta of 1.83. Milestone Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $2.75. The stock has a fifty day moving average of $2.02 and a 200 day moving average of $1.81. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Atria Investments Inc boosted its stake in Milestone Pharmaceuticals by 44.4% during the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after buying an additional 12,430 shares during the period. PVG Asset Management Corp bought a new stake in Milestone Pharmaceuticals during the third quarter valued at $46,000. Northern Trust Corp lifted its stake in Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after purchasing an additional 30,772 shares during the last quarter. Toronto Dominion Bank bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $1,770,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth about $73,000. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.